172 related articles for article (PubMed ID: 19199905)
1. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma.
Frankel AE; Zuckero SL; Mankin AA; Grable M; Mitchell K; Lee YJ; Neville DM; Woo JH
Curr Drug Targets; 2009 Feb; 10(2):104-9. PubMed ID: 19199905
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials.
Woo JH; Lee YJ; Neville DM; Frankel AE
Methods Mol Biol; 2010; 651():157-75. PubMed ID: 20686966
[TBL] [Abstract][Full Text] [Related]
3. Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.
Frankel AE; Woo JH; Ahn C; Foss FM; Duvic M; Neville PH; Neville DM
Haematologica; 2015 Jun; 100(6):794-800. PubMed ID: 25795722
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
[TBL] [Abstract][Full Text] [Related]
5. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion.
Thompson J; Stavrou S; Weetall M; Hexham JM; Digan ME; Wang Z; Woo JH; Yu Y; Mathias A; Liu YY; Ma S; Gordienko I; Lake P; Neville DM
Protein Eng; 2001 Dec; 14(12):1035-41. PubMed ID: 11809934
[TBL] [Abstract][Full Text] [Related]
6. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma.
Duvic M; Cather J; Maize J; Frankel AE
Am J Hematol; 1998 May; 58(1):87-90. PubMed ID: 9590158
[TBL] [Abstract][Full Text] [Related]
7. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1).
Woo JH; Bour SH; Dang T; Lee YJ; Park SK; Andreas E; Kang SH; Liu JS; Neville DM; Frankel AE
Cancer Immunol Immunother; 2008 Aug; 57(8):1225-39. PubMed ID: 18256829
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.
Kreitman RJ; Chaudhary VK; Waldmann TA; Hanchard B; Cranston B; FitzGerald DJ; Pastan I
Leukemia; 1993 Apr; 7(4):553-62. PubMed ID: 8464234
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
Foss FM
Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
[TBL] [Abstract][Full Text] [Related]
10. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.
Foss FM; Bacha P; Osann KE; Demierre MF; Bell T; Kuzel T
Clin Lymphoma; 2001 Mar; 1(4):298-302. PubMed ID: 11707845
[TBL] [Abstract][Full Text] [Related]
11. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
Kreitman RJ
BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
[TBL] [Abstract][Full Text] [Related]
12. Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2).
Meneghetti CM; LeMaistre CF
Targeted Diagn Ther; 1992; 7():395-401. PubMed ID: 1633301
[No Abstract] [Full Text] [Related]
13. Reversal of acute allograft rejection using immunotoxin.
Knechtle SJ; Fechner JH; Stavrou S; Neville DM; Dong Y; Hong X; Tsuchida M; Hamawy MM
Transplant Proc; 1998 Aug; 30(5):2150-1. PubMed ID: 9723422
[No Abstract] [Full Text] [Related]
14. T-cell depletion and graft survival induced by anti-human CD3 immunotoxins in human CD3epsilon transgenic mice.
Weetall M; Digan ME; Hugo R; Mathew S; Hopf C; Tart-Risher N; Zhang J; Shi V; Fu F; Hammond-McKibben D; West S; Brack R; Brinkmann V; Bergman R; Neville D; Lake P
Transplantation; 2002 May; 73(10):1658-66. PubMed ID: 12042656
[TBL] [Abstract][Full Text] [Related]
15. Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor.
Vallera DA; Panoskaltsis-Mortari A; Jost C; Ramakrishnan S; Eide CR; Kreitman RJ; Nicholls PJ; Pennell C; Blazar BR
Blood; 1996 Sep; 88(6):2342-53. PubMed ID: 8822957
[TBL] [Abstract][Full Text] [Related]
16. Development of a diphtheria toxin based antiporcine CD3 recombinant immunotoxin.
Wang Z; Duran-Struuck R; Crepeau R; Matar A; Hanekamp I; Srinivasan S; Neville DM; Sachs DH; Huang CA
Bioconjug Chem; 2011 Oct; 22(10):2014-20. PubMed ID: 21866954
[TBL] [Abstract][Full Text] [Related]
17. Effect of pre-existing anti-diphtheria toxin antibodies on T cell depletion levels following diphtheria toxin-based recombinant anti-monkey CD3 immunotoxin treatment.
Matar AJ; Pathiraja V; Wang Z; Duran-Struuck R; Gusha A; Crepeau R; Tasaki M; Sachs DH; Huang CA
Transpl Immunol; 2012 Aug; 27(1):52-4. PubMed ID: 22676970
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
[TBL] [Abstract][Full Text] [Related]
19. An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood.
Thompson J; Hu H; Scharff J; Neville DM
J Biol Chem; 1995 Nov; 270(47):28037-41. PubMed ID: 7499288
[TBL] [Abstract][Full Text] [Related]
20. New advances in the management of cutaneous T-cell lymphoma.
Young SK
Cancer Pract; 2001; 9(1):52-4. PubMed ID: 11879274
[No Abstract] [Full Text] [Related]
[Next] [New Search]
